Want to join the conversation?
Joshua Jennings of Cowen & Co. asks about biosimilar competition to the REMICADE franchise in 2017 and beyond. $JNJ CFO Dominic Caruso said the company does not expect biosimilar competition in 2016. $JNJ has several patents that it intends to defend. Overall, the immunology franchise is very strong and remain comfortable with the growth outlook.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.